title: Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.
abstract: We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8% of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinico-pathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, yet is not a useful prognostic marker.
authors.affiliation: Department of Obstetrics and Gynecology, Okayama University Medical School, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Seki
authors.forename: M
authors.initials: M
authors.lastname: Yoshinouchi
authors.forename: N
authors.initials: N
authors.lastname: Seki
authors.forename: J
authors.initials: J
authors.lastname: Kodama
authors.forename: Y
authors.initials: Y
authors.lastname: Miyagi
authors.forename: T
authors.initials: T
authors.lastname: Kudo
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D018394:CA-125 Antigen / Q000097:blood; D002277:Carcinoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005260:Female; D051518:Fibroblast Growth Factor 3; D005346:Fibroblast Growth Factors / Q000032:analysis / Q000235:genetics*; D005500:Follow-Up Studies; D005784:Gene Amplification; D018734:Genes, erbB-2; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011518:Proto-Oncogene Proteins / Q000032:analysis / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000235:genetics*; D015996:Survival Rate; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D051518:Fibroblast Growth Factor 3; D005346:Fibroblast Growth Factors; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C496444:FGF3 protein, human